DnB Asset Management’s Epizyme, Inc EPZM Stock Holding History

DnB Asset Management’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-20,744	Closed	-$225K	–	654
2020 Q4	$225K	Buy	+20,744	New	+$256K	﹤0.01%	624

Other funds holding EPZM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KXA

KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

DnB Asset Management's EPZM Position: Q1 2021 in Review

DnB Asset Management sold out of Epizyme, Inc (EPZM) in Q1 2021, closing a stake of 20,744 shares — an estimated $225K sold.

DnB Asset Management first reported a position in EPZM in Q4 2020 and held it in 1 quarter. The position peaked at $225K in Q4 2020. 137 funds tracked by Wall St. Rank hold EPZM as of Q1 2021.

DnB Asset Management reported no remaining Epizyme, Inc position as of Q1 2021 after selling out during the quarter.
DnB Asset Management sold 20,744 Epizyme, Inc shares in Q1 2021, an estimated $225K.
DnB Asset Management first reported a position in Epizyme, Inc in Q4 2020 and held it in 1 quarter.
DnB Asset Management's Epizyme, Inc position peaked at $225K in Q4 2020.
137 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2021.

Based on DnB Asset Management's 13F filing for Q1 2021, filed 15 Apr 2021.